Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Soluble CD146 in Patients With Recurrent Glioblastoma Treated by Bevacizumab

NCT06001281 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT06001281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Soluble CD146 in Patients With Recurrent Glioblastoma Treated by Bevacizumab
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Not applicable
Overall status
Recruiting
Start date
January 30, 2024
Completion date
December 31, 2026
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma